Femasys (NASDAQ:FEMY) CFO Dov Elefant Buys 15,625 Shares of Stock

Femasys Inc. (NASDAQ:FEMY) CFO Dov Elefant purchased 15,625 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were acquired at an average cost of $3.20 per share, with a total value of $50,000.00. Following the completion of the purchase, the chief financial officer owned 15,625 shares of the company’s stock, valued at $50,000. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Femasys Trading Down 0.8%

NASDAQ FEMY traded down $0.02 during trading hours on Tuesday, hitting $2.35. The company’s stock had a trading volume of 228,436 shares, compared to its average volume of 120,035. Femasys Inc. has a twelve month low of $2.29 and a twelve month high of $22.20. The firm has a market capitalization of $7.10 million, a P/E ratio of -0.44 and a beta of -2.08. The company has a quick ratio of 1.98, a current ratio of 3.91 and a debt-to-equity ratio of 0.53. The stock has a fifty day moving average of $3.87 and a 200 day moving average of $7.49.

Femasys (NASDAQ:FEMY) last released its earnings results on Friday, May 8th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($1.33) by $1.43. The firm had revenue of $0.42 million during the quarter, compared to analyst estimates of $0.77 million. Femasys had a negative net margin of 521.97% and a negative return on equity of 258.08%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp grew its stake in Femasys by 43.5% in the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after acquiring an additional 24,500 shares during the period. Kovack Advisors Inc. acquired a new stake in shares of Femasys during the fourth quarter worth about $27,000. Osaic Holdings Inc. bought a new position in shares of Femasys during the 2nd quarter valued at about $45,000. HRT Financial LP bought a new position in shares of Femasys during the 4th quarter valued at about $30,000. Finally, Cetera Investment Advisers acquired a new position in shares of Femasys in the 4th quarter valued at approximately $36,000. 65.27% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Weiss Ratings raised Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Wall Street Zen raised Femasys to a “hold” rating in a research note on Saturday, June 13th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Femasys has a consensus rating of “Hold” and an average price target of $80.00.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.